Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 3/20 | 0.67 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.60 |
| ▸ | PRKACA | P17612 | 2/20 | 0.60 |
| ▸ | PRKX | P51817 | 2/20 | 0.60 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | GSK3A | P49840 | 1/20 | 0.60 |
| ▸ | GSK3B | P49841 | 1/20 | 0.60 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.60 |
| ▸ | GRK5 | P34947 | 1/20 | 0.57 |
| ▸ | NAMPT | P43490 | 2/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1767413 | 0.95 | MMP13 (0.61) | MMP13ROCK1AURKAHPGDLMNA | |
| SCHEMBL1767505 | 0.90 | KDM4E (0.59) | MMP13ROCK1ROCK2MAPK14TP53 | |
| SCHEMBL1767497 | 0.89 | NPC1 (0.60) | HPGDLMNACYP2D6CYP2C9MAPK14 | |
| SCHEMBL1767521 | 0.89 | HDAC1 (0.62) | MMP13LMNAMAPK14KMT2ATP53 | |
| SCHEMBL1767513 | 0.86 | HTT (0.61) | ROCK1LMNAROCK2PRKACAPRKX | |
| SCHEMBL7134254 | 0.85 | MMP13 (0.86) | MMP13ROCK1AURKAHPGDLMNA | |
| SCHEMBL1767407 | 0.84 | KDM5A (0.61) | AURKALMNAROCK2NAMPTKMT2A | |
| SCHEMBL1767368 | 0.84 | NPC1 (0.59) | LMNACYP2D6CYP2C9MAPK14TP53 | |
| SCHEMBL5209384 | 0.82 | MMP13 (0.72) | MMP13ROCK1AURKAHPGDLMNA | |
| SCHEMBL1568252 | 0.81 | ROCK2 (0.86) | MMP13ROCK1AURKAHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160289191-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2016-10-06 | — | — | US | disclosed |
| US-20160289191-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2016-10-06 | — | — | US | disclosed |
| US-9187426-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-11-17 | — | — | US | disclosed |
| US-9187426-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-11-17 | — | — | US | disclosed |
| CN-102119152-B | Organic compounds | NOVARTIS AG | 2014-07-02 | — | — | CN | disclosed |
| CN-102119152-A | Organic compounds | NOVARTIS AG | 2011-07-06 | — | — | CN | disclosed |
| US-20110105530-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-05-05 | — | — | US | disclosed |
| US-20110105530-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-05-05 | — | — | US | disclosed |
| WO-2009156484-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105530-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | MMP13 1303/4885ROCK1 4244/4885AURKA 2161/4885 |
| US-20160289191-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | MMP13 1303/4885ROCK1 4244/4885AURKA 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.